Your browser doesn't support javascript.
loading
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
Kirk, Peter S; Zhu, Kehao; Zheng, Yingye; Newcomb, Lisa F; Schenk, Jeannette M; Brooks, James D; Carroll, Peter R; Dash, Atreya; Ellis, William J; Filson, Christopher P; Gleave, Martin E; Liss, Michael; Martin, Frances; McKenney, Jesse K; Morgan, Todd M; Nelson, Peter S; Thompson, Ian M; Wagner, Andrew A; Lin, Daniel W; Gore, John L.
Afiliación
  • Kirk PS; Department of Urology, University of Washington, Seattle, Washington.
  • Zhu K; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Zheng Y; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Newcomb LF; Department of Urology, University of Washington, Seattle, Washington.
  • Schenk JM; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Brooks JD; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Carroll PR; Department of Urology, Stanford University, Stanford, California.
  • Dash A; Department of Urology, University of California, San Francisco, California.
  • Ellis WJ; VA Puget Sound Health Care Systems, Seattle, Washington.
  • Filson CP; Department of Urology, University of Washington, Seattle, Washington.
  • Gleave ME; Department of Urology, Emory University, Atlanta, Georgia.
  • Liss M; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Martin F; Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas.
  • McKenney JK; Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia.
  • Morgan TM; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
  • Nelson PS; Department of Urology, University of Michigan, Ann Arbor, Michigan.
  • Thompson IM; Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Wagner AA; CHRISTUS Medical Center Hospital, San Antonio, Texas.
  • Lin DW; Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Gore JL; Department of Urology, University of Washington, Seattle, Washington.
Cancer ; 128(2): 269-274, 2022 Jan 15.
Article en En | MEDLINE | ID: mdl-34516660
ABSTRACT

BACKGROUND:

Maintaining men on active surveillance for prostate cancer can be challenging. Although most men who eventually undergo treatment have experienced clinical progression, a smaller subset elects treatment in the absence of disease reclassification. This study sought to understand factors associated with treatment in a large, contemporary, prospective cohort.

METHODS:

This study identified 1789 men in the Canary Prostate Cancer Active Surveillance Study cohort enrolled as of 2020 with a median follow-up of 5.6 years. Clinical and demographic data as well as information on patient-reported quality of life and urinary symptoms were used in multivariable Cox proportional hazards regression models to identify factors associated with the time to treatment

RESULTS:

Within 4 years of their diagnosis, 33% of men (95% confidence interval [CI], 30%-35%) underwent treatment, and 10% (95% CI, 9%-12%) were treated in the absence of reclassification. The most significant factor associated with any treatment was an increasing Gleason grade group (adjusted hazard ratio [aHR], 14.5; 95% CI, 11.7-17.9). Urinary quality-of-life scores were associated with treatment without reclassification (aHR comparing "mostly dissatisfied/terrible" with "pleased/mixed," 2.65; 95% CI, 1.54-4.59). In a subset analysis (n = 692), married men, compared with single men, were more likely to undergo treatment in the absence of reclassification (aHR, 2.63; 95% CI, 1.04-6.66).

CONCLUSIONS:

A substantial number of men with prostate cancer undergo treatment in the absence of clinical changes in their cancers, and quality-of-life changes and marital status may be important factors in these decisions. LAY

SUMMARY:

This analysis of men on active surveillance for prostate cancer shows that approximately 1 in 10 men will decide to be treated within 4 years of their diagnosis even if their cancer is stable. These choices may be related in part to quality-or-life or spousal concerns.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Espera Vigilante Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Espera Vigilante Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article